enveric.com (ENVB): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Enveric Biosciences (ENVB) is developing non-hallucinogenic medications to treat anxiety by leveraging its unique Psybrary archive of synthetic compounds. The company is recognized as an authoritative developer in the mental health sector due to its commitment to a scientific approach. This EV/EBITDA chart currently reflects a level of 0.00. Growth prospects depend on approvals from the FDA and DEA, as current capital is supported by patents without active sales.

ENVB Enveric Biosciences Inc: Enterprise Value to EBITDA Ratio in the range 11/23/2025 - 11/11/2026

enveric.com - analytical breakdowns and key metrics (ENVB)

- current price and projected stock value:

Stock Price Enveric|ENVB - Analyst Consensus Forecast

- stock exchange capitalization data:

Market Value Enveric Corp|ENVB - Value Adjusted for Debt and Cash

- book value of equity indicators:

Net Assets per Single Share Enveric Biosciences|ENVB - Company Net Assets|Market Capitalization to Book Value Ratio enveric.com|ENVB - Company Assets

- debt and solvency information:

- business earnings and investment ratios data:

ENVB - Net Financial Result|Projected Future Earnings Enveric Biosciences|ENVB - Price to Earnings Ratio|Projected Price to Earnings Enveric Biosciences|ENVB - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Enveric Corp|ENVB - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Enveric Biosciences|ENVB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months enveric.com|ENVB - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Enveric Biosciences

Summary company analytics:Enveric ENVB

Original product of Enveric Biosciences Inc

Investors are evaluating the fundamental potential of Enveric Biosciences (ENVB) through the lens of business value relative to its operating profit. This ratio compares total enterprise value, including debt, to EBITDA, excluding the impact of taxes and depreciation to reveal the actual efficiency of assets. Analyzing the EV/EBITDA metric, accounting for depreciation and debt, is critical, as it reflects the extent of the premium paid for future commercial success in depression therapies during the psychedelic drug development stage.

Competitor analysis

EV/EBITDA Multiple INDV (Indivior Group)|EV/EBITDA Multiple Collegium Corp COLL|CRON - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Business Value to Operating Income Before Depreciation CGC (canopygrowth.com)|High Tide (HITI) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Aurora Cannabis Inc.|ACHV (Achieve Life Sciences, Inc) - EV/EBITDA Multiple|Company Value to EBITDA skyebioscience.com SKYE|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Anebulo Pharmaceuticals (ANEB)|intercure.co - Enterprise Value to Operating Income Before Depreciation|Nutriband - Enterprise Value to EBITDA Ratio|Nasus Pharma Ltd. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IGC Pharma Inc - EV/EBITDA Multiple|Company Value to EBITDA MIRA Pharmaceuticals|Flora Growth Corp. (FLGC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IM Cannabis - Business Value to Operating Income Before Depreciation|ADIL (Adial Pharmaceuticals Inc.) - EV/EBITDA Multiple|Artelo (ARTL) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple ENSC|Enterprise Value to EBITDA Ratio titanpharm.com TTNP|Greenlane Holdings - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation INM|Akanda Corp. - EV/EBITDA Multiple|BGXX: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HPCO: EV/EBITDA Multiple